Breast Cancer Clinical Trial
Official title:
Evaluation of the LightPath® Imaging System and the PET Tracer 68Ga-RM2 in Wide Local Excision (WLE) for Breast Cancer
This study is a prospective, open-label study to examine the performance of the LightPath®
Imaging System using the PET tracer 68Ga-RM2 in patients scheduled for and/or undergoing wide
local excision (WLE) with or without sentinel lymph node biopsy (SLNB) or complete axillary
lymph node dissection(cALND) for breast cancer with an ER-positive invasive primary cancer.
The study consists of 3 sequential groups:
Group 1 (N=20 patients): Torso, i.e. base of skull to thighs, PET/CT imaging and axillary
gamma probe measurements (using a collimator) of 68Ga-RM2 to: determine the optimal scan
time-window post-injection; to extrapolate the optimal dose for resolution against axillary
background signal on gamma probe measurements (first 6 patients); and the value of 68Ga-RM2
PET/CT imaging for breast cancer staging (all 20 patients).
Group 2 (N=10 patients): Intraoperative LightPath® imaging with 68Ga-RM2 to familiarise site
with procedure and interpretation of intraoperative scans,validate the dose and timings
determined from Group 1, and optimise LightPath® Imaging parameters such as acquisition
resolution and duration. Group 2 scans will acquire LightPath® images of both intact and
incised cancer specimens for post-operative standardised, controlled assessment. Group 2 will
use the optimal scan time-window and 68Ga-RM2 activity extrapolated from at least the first 6
patients in Group 1. The dose of 68Ga-RM2 will be determined to optimise the intra-operative
imaging and axillary gamma probe measurements.
Group 3 (N=50 patients): Intraoperative LightPath® imaging with 68Ga-RM2 to measure agreement
between LightPath® images and post-operative histopathology. Group 3 scans will acquire
LightPath® images of intact and incised cancer specimens for post-operative standardised,
controlled assessment. Group 3 will use the optimal scan time-window and 68Ga-RM2 activity
extrapolated from the first 6 patients in Group 1 with the optimised imaging parameters, and
dose developed from Group 2.
The intraoperative LightPath® Images will be used to inform the surgeons about detectable
residual cancer in an attempt to achieve better guided cancer surgery and complete tumour
excision with clear WLE resection margins
The study site will use the local criteria considered standard of care to guide decisions to
act on positive margins. Lightpoint Medical will provide guidance to act on LightPath® Images
in the Instructions forUse (IFU). It will be at the Investigator's discretion to choose
whether to act based upon the intraoperative LightPath® Images.
In Group 3,the resection margin status of the WLE specimen, cavity shavings (if any) and the
metastatic status of axillary (sentinel) lymph nodes as measured with the LightPath® Imaging
System will be compared with histopathology results. A positive margin on histology will be
defined as
- Invasive carcinoma: positive: ink on tumour; close: <1mm; negative ≥1mm
- Ductal carcinoma in situ (DCIS)or pleomorphic lobular carcinoma in situ (LCIS) (if
present): positive: ink on tumour; close: <2mm; negative ≥2mm.
Status | Not yet recruiting |
Enrollment | 80 |
Est. completion date | November 2023 |
Est. primary completion date | November 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Subjects who have signed an informed consent form prior to any study related activity - Subjects who are able to give voluntary, written informed consent to participate in this study. - Subjects who are able to understand this study and are willing to complete all the study assessments - Female subjects =18 years of age with a diagnosis of ER-positive invasive breast cancer. ER-positivity is defined as an Allred score of 3 or more on immunohistochemical analysis. - Female subjects of childbearing age must have a negative pregnancy test (by Beta HCG qualitative analysis), or must have had a history of a surgical sterilisation, or must give history of no menses in the past twelve months - Groups 2 and 3: Subjects scheduled for WLE +/-SLNB or ALND Exclusion Criteria: - Subjects who have had surgery in the operated breast in the past 12months - Subjects who have had radiotherapy in the operated breast - Subjects who have had neoadjuvant systemic therapy - Subjects who have had systemic chemotherapy or investigational therapy in the past two years - Subjects who are pregnant or lactating - Subjects who have a known hypersensitivity to 68Ga, bombesin analogues, or GRPR-antagonists - Subjects who have an existing medical condition that would compromise their participation in the study•Subjects with a current or active history of other known cancerin the opinion of the Investigator |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Guy's and St Thomas' NHS Foundation Trust | London |
Lead Sponsor | Collaborator |
---|---|
Lightpoint Medical Limited |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Association between PET and/or LightPath® results and biomarkers (ER, PR, HER2, other according to local practice) | Exploratory Outcome Measures | up to 5 year | |
Other | Study-related adverse events (AEs) | Exploratory Outcome Measures | up to 5 year | |
Other | Lymph node involvement by LightPath® Image (compared with histology: macrometastasis, micrometastasis, or isolated tumour cells) | Exploratory Outcome Measures | up to 5 year | |
Other | Agreement between 68Ga-RM2 and gastrin-releasing peptide receptor (GRPR) immunohistochemistry | Exploratory Outcome Measures | up to 5 year | |
Primary | Diagnostic performance of LightPath® Imaging System | Agreement between margin status determined by LightPath® Imaging and post-operative histopathology (Group 3) | up to 5 year | |
Secondary | Optimal scan time-window for 68Ga-RM2 PET/CT imaging | Group 1 only | 1 year | |
Secondary | Gamma probe measurements (collimated) in the axilla to determine optimal 68Ga-RM2 activity | Group 1 only | 1 year | |
Secondary | Value of 68Ga-RM2 PET/CT imaging for breast cancer staging | Group 1 only | 1 year | |
Secondary | Radiation dosimetry measurements for the staff | Group 1 only | 1 year | |
Secondary | Optimal device settings, tracer dose, and working procedures | Group 2 only | up to 2 years | |
Secondary | Inter-rater agreement in post-operative standardised, controlled assessments of LightPath® Images | Group 3 only | up to 5 year | |
Secondary | MDT decision to re-operate at index location | Group 3 only | up to 5 year | |
Secondary | Weight of primary lump and lump plus shavings | Groups 2 and 3 only | up to 5 year | |
Secondary | Radiation dosimetry for operating room and recovery area staff | Groups 2 and 3 only | up to 5 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |